Project Grant R61HL174736
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $774,229 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Kaiser Foundation Hospitals in Oakland, CA. The grant, titled "Understanding the Impact of Early Life Factors on Cardiometabolic Risk Throughout the Life Course in a Large and Diverse Cohort of Adolescents and Young Adults", aims to conduct a large longitudinal cohort study to better understand the epidemiology of cardiometabolic outcomes...
- This National Heart Lung and Blood Institute (NHLBI) Project Grant award for $147,486 aims to investigate the role of high-fat diet in hematopoiesis (blood cell formation) and clonal hematopoiesis (CH), which is associated with increased risk of myeloid diseases like myelodysplastic syndrome and acute myeloid leukemia in the elderly. The award, under the CFDA 93.837 Cardiovascular Diseases Research program, supports research at the University of Michigan to study the impact of aging and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,364,153 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New York University's NYU Long Island School of Medicine to conduct research on reducing plasma cholesterol and atherosclerosis using a microRNA-30c analog called C2. The project aims to identify novel ways to reduce plasma cholesterol levels and the risk of developing cardiovascular disease. The key objectives are to investigate the molecular mechanisms by...
- This $1,057,905 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a comprehensive research program to promote weight-related health and address the full spectrum of weight-related outcomes in the next generation of adolescents and young adults. The project, titled "PROMOTING WEIGHT-RELATED HEALTH IN THE NEXT GENERATION OF ADOLESCENTS AND YOUNG ADULTS," aims to understand the most salient issues facing...
- This $747,281 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop a real-time, non-invasive method for characterizing the mechanical properties of blood clots (thrombi) as they age. The goal is to create an ultrasound-based micro-rheology technique that can spatiotemporally quantify evolving thrombus characteristics like age and elasticity in real-time. This is intended to improve understanding...
- This $548,816 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Illinois focused on understanding the role of the SEC16B protein in regulating lipid metabolism and the formation of lipid droplets in the liver. The goal is to elucidate the function and mechanisms by which SEC16B modulates very low-density lipoprotein (VLDL) secretion and lipid droplet dynamics, which are key processes in...
- The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $167,400 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dr. Joshua Meisner at the University of Michigan. The award aims to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by truncating variants of the MYBPC3 gene, a leading cause of sudden cardiac death and heart failure, especially in children and adolescents....
- This federal Project Grant award of $256,785, awarded on September 15, 2025 by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), will fund research to identify genetic factors that influence blood levels of acetylcarnitine, a metabolite associated with sepsis-induced organ dysfunction and mortality. The research will leverage existing biospecimens and data from the CLOVERS trial to conduct a metabolomics-genome-wide association study (GWAS). The goal...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $392,037 Project Grant to New York University (NYU) to support research on post-operative biomarker-guided precision medicine for cardiovascular risk reduction. The goal is to carry out an international multi-site randomized clinical trial to evaluate perioperative biomarker-based precision care, using targeted long-term use of low-dose direct oral anticoagulants and...
- This Project Grant award, in the amount of $791,485.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research by the University of Pittsburgh to develop an ultrasound-based approach for the targeted delivery of microRNA-92a inhibitors to treat adverse left ventricular remodeling following acute myocardial infarction. The project aims to advance the clinical translation of this...
This Project Grant award is provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $644,415 grant, awarded on Sep 19, 2025, funds a sequential multiple assignment randomized trial of diet treatments for improving hepatic steatosis and cardiometabolic risk in adolescents. The research will be conducted by Michigan State University (MSU) and aims to develop an efficacious, precise adaptive intervention strategy using a registered dietitian-provided very low-sugar diet and essential amino acid supplements. The goal is to optimize outcomes for youth with metabolic-dysfunction associated steatotic liver disease, which is an independent risk factor for atherosclerotic cardiovascular disease. The project will run through July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $644.4k | 9/15/25 |